SCHEMBL8399407

SCHEMBL8399407

CC(C)OP(N)(=O)OC(C)C

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.50
ACHE P22303 1/20 0.50
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22824211 0.83 CTSA (0.37) CTSAACHEALDH1A1KDM4EPOLB
SCHEMBL11884745 0.79 TSHR (0.42) CTSAACHEALDH1A1KDM4EPOLB
SCHEMBL22921227 0.78
SCHEMBL21764561 0.77 TSHR (0.39) CTSAACHEALDH1A1KDM4EPOLB
SCHEMBL11152845 0.75 CTSA (0.33) CTSAACHE
SCHEMBL19348752 0.75
SCHEMBL8399409 0.75
SCHEMBL19837949 0.74 CTSA (0.39) CTSAACHEALDH1A1KDM4EPOLB
SCHEMBL19837950 0.74 CTSA (0.39) CTSAACHEALDH1A1KDM4EPOLB
SCHEMBL3693476 0.73 CTSA (0.32) CTSAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110461157-B Herbicidal mixtures 拜耳公司 2021-11-02 CN claimed
EP-0678096-A1 SYNTHESIS OF DIMMER BLOCKS AND THEIR USE IN ASSEMBLING OLIGONUCLEOTIDES. HYBRIDON INC (US) 1995-10-25 EP claimed
WO-1994015946-A1 SYNTHESIS OF DIMMER BLOCKS AND THEIR USE IN ASSEMBLING OLIGONUCLEOTIDES HYBRIDON, INC. (US) 1994-07-21 WO claimed
EP-4720050-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2026-04-08 EP disclosed
WO-2024249672-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2024-12-05 WO disclosed
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALPHA-9 ONCOLOGY INC. (CA) 2024-01-18 US disclosed
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALPHA-9 ONCOLOGY INC. (CA) 2024-01-18 US disclosed
US-20230114807-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-04-13 US disclosed
CN-110325543-B Cyclic dinucleotides as STING (stimulator of interferon genes) agonists 武田药品工业株式会社 2023-03-31 CN disclosed
WO-2022126275-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-06-23 WO disclosed
US-20210338851-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2021-11-04 US disclosed
US-5744465-A Method of inhibiting a β-lactamase enzyme by administering novel 2-thiosubstituted carbapenems AMERICAN CYANAMID COMPANY (US) 1998-04-28 US disclosed
US-5623081-A USING BENZYLOXYACETALDEHYDE DIMETHYL ETHER, HALOGENATED 1-PHENYLMETHOXY-4-PENTEN-2-OL; CYCLIZATION LIN YANG-I (US) 1997-04-22 US disclosed
US-5602118-A A 2-((2-SUBSTITUTED ALKYL)FUR-3-YL)-THIO-),3-CARBOXY-2-CARBOPENEM DERIVATIVES; EFFECTIVE AGAINST BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA AMERICAN CYANAMID COMPANY (US) 1997-02-11 US disclosed
CN-1104214-A Novel 2-thiocarbpenems AMERICAN CRANAMID COMPANY (US) 1995-06-28 CN disclosed
EP-0444119-B1 PROCESS FOR PRODUCING cDNA DYNAL AS (NO) 1995-05-17 EP disclosed
EP-0444119-A1 PROCESS FOR PRODUCING cDNA. HOLMES MICHAEL JOHN (GB) 1991-09-04 EP disclosed
US-4975425-A COMPOSITION FORMED FROM ALCOHOL, A MODIFIED COCODIETHANOLAMIDE AND WATER; RAPID ABSORPTION MOBAY CORPORATION (US) 1990-12-04 US disclosed
WO-1990006044-A2 PROCESS FOR PRODUCING cDNA DYNAL AS (NO) 1990-06-14 WO disclosed
US-4059532-A CELLULOSE CIBA-GEIGY CORPORATION (US) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338851-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOLH1, KLK3, PSMA3 CTSA 2046/4885ACHE 3501/4885ALDH1A1 2773/4885
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN KLK3, FOLH1, TMEM14C CTSA 1275/4885ACHE 4425/4885ALDH1A1 2048/4885
US-20230114807-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOLH1, KLK3, PSMA3 CTSA 2046/4885ACHE 3501/4885ALDH1A1 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.